Patents by Inventor Arvin Dar

Arvin Dar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS
    Publication number: 20230404985
    Abstract: The present disclosure relates to methods of treating tumors and cancers having dysregulated Wnt signaling pathways with compounds of Formula (I) having the following structure: (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where X is a halogen and R is a phenyl substituted with a perfluoroalkane. Also disclosed is a method of treating a tumor, which involves contacting a tumor comprising cytoplasmic EZH2 with a kinase inhibitor compound under conditions effective to treat the tumor.
    Type: Application
    Filed: November 2, 2021
    Publication date: December 21, 2023
    Inventors: Ernesto GUCCIONE, Amaia LUJAMBIO, Arvin DAR, Alexander RIALDI, Mary E. DUFFY, Alexander P. SCOPTON, Pedro MOLINA-SANCHEZ, Slim MZOUGHI
  • SMALL MOLECULE MODULATORS OF KSR-BOUND MEK
    Publication number: 20230381180
    Abstract: An ATP non-competitive inhibitor of mitogen-activated protein kinase (MEK), inter alia, human MEK (MEK1 or MEK2) having the properties: (i) allosterically binds an inhibitor pocket formed at an interaction interface between human MEK (MEK1 or MEK2) and human Kinase Suppressor of Ras (KSR1 or KSR2 or BRAF) adjacent to ATP in a physiological complex between MEK and KSR (or BRAF), forming an inhibitor-inhibitor pocket complex; (ii) is an ATP non-competitive kinase inhibitor; (iii) a structure such that when bound to the inhibitor-inhibitor pocket complex, the complex comprises the structural elements: (a) at least one moiety of the inhibitor engaging A825 of KSR1, or P878 of KSR2; or R662 of BRAF (b) at least one moiety engaging R234 of MEK, wherein where R234 is within 5 ? from any atoms of KSR1 or KSR2 or BRAF is disclosed.
    Type: Application
    Filed: January 8, 2021
    Publication date: November 30, 2023
    Inventors: Arvin Dar, Alexander P. Scopton, Jayasudhan Reddy Yerabolu, Zaigham M. Khan, Alexander Michael Real, William Michael Marsiglia
  • LIVE CELL ENGAGEMENT ASSAY
    Publication number: 20230266321
    Abstract: A detectable probe comprising a moiety, which is an ATP non-competitive inhibitor of mitogen-activated protein kinase (MEK), inter alia, human MEK (MEK1 or MEK2) having the properties: (i) allosterically binds an inhibitor pocket formed at an interaction interface between human MEK (MEK1 or MEK2) and human Kinase Suppressor of Ras (KSR1 or KSR2 orBRAF) adjacent to ATP in a physiological complex between MEK and KSR (or BRAF), forming an inhibitor-inhibitor pocket complex; (ii) is an ATP non-competitive kinase inhibitor; (iii) a structure such that when bound to the inhibitor-inhibitor pocket complex, the complex comprises the structural elements: (a) at least one moiety of the inhibitor engaging A825 of KSR1, or P878 of KSR2; or R662 of BRAF (b) at least one moiety engaging R234 of MEK, wherein where R234 is within 5 A from any atoms of KSR1 or KSR2 or BRAF is disclosed. The probe further comprises a detectable label conjugated directly or through a linker to the inhibitor moiety.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Arvin Dar, Zaigham M. Khan, William Michael Marsiglia
  • KSR antagonists
    Patent number: 10548897
    Abstract: This invention relates to antagonists of Kinase Suppressor of Ras (KSR). Pharmaceutical compositions comprising KSR inhibitors and methods of treating cancer are also provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 4, 2020
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Arvin Dar, Neil Dhawan, Alex P. Scopton
  • KSR Antagonists
    Publication number: 20180256577
    Abstract: This invention relates to antagonists of Kinase Suppressor of Ras (KSR). Pharmaceutical compositions comprising KSR inhibitors and methods of treating cancer are also provided.
    Type: Application
    Filed: April 15, 2016
    Publication date: September 13, 2018
    Inventors: Arvin Dar, Neil Dhawan, Alex P. Scopton
  • Methods and compositions for modulating Ire1, SRC and ABL activity
    Patent number: 9382230
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 5, 2016
    Assignee: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • Methods of inhibiting Ire1
    Patent number: 8980899
    Abstract: Disclosed herein are, inter alia, methods for inhibiting Ire1 activity.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: March 17, 2015
    Assignee: The Regents of the University of California
    Inventors: Alexei Korennykh, Peter Walter, Han Li, Arvin Dar, Kevan Shokat
  • METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY
    Publication number: 20150011575
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • Methods and compositions for modulating IRE1, SRC, and ABL activity
    Patent number: 8815885
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: August 26, 2014
    Assignee: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • Fused ring heteroaryl kinase inhibitors
    Patent number: 8697709
    Abstract: Provided herein are fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 15, 2014
    Assignee: The Regents of the University of California
    Inventors: Arvin Dar, Kevan M Shokat
  • METHODS OF INHIBITING IRE1
    Publication number: 20120322814
    Abstract: Disclosed herein are, inter alia, methods for inhibiting Ire1 activity.
    Type: Application
    Filed: October 18, 2010
    Publication date: December 20, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Alexei Korennykh, Peter Walter, Han Li, Arvin Dar, Kevan Shokat
  • Methods and Compositions for Modulating IRE1, SRC, and ABL Activity
    Publication number: 20110319436
    Abstract: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
    Type: Application
    Filed: September 15, 2009
    Publication date: December 29, 2011
    Applicant: The Regents of the University of California
    Inventors: Peter Walter, Alexei Korennykh, Kevan M. Shokat, Chao Zhang, Janet Finer-Moore, Robert Stroud, Pascal Egea, Andrei Korostelev, Arvin Dar, Sebastian Bernales
  • FUSED RING HETEROARYL KINASE INHIBITORS
    Publication number: 20110275651
    Abstract: Provided herein are fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states.
    Type: Application
    Filed: October 16, 2009
    Publication date: November 10, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Arvin Dar, Kevan M. Shokat